MA40781A - Composition pharmaceutique d'isotrétinoïne à faible dosage destinée à la voie orale - Google Patents
Composition pharmaceutique d'isotrétinoïne à faible dosage destinée à la voie oraleInfo
- Publication number
- MA40781A MA40781A MA040781A MA40781A MA40781A MA 40781 A MA40781 A MA 40781A MA 040781 A MA040781 A MA 040781A MA 40781 A MA40781 A MA 40781A MA 40781 A MA40781 A MA 40781A
- Authority
- MA
- Morocco
- Prior art keywords
- isotretinoin
- pharmaceutical composition
- oral use
- low dosage
- dosage
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Botany (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2827DE2014 | 2014-10-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA40781A true MA40781A (fr) | 2017-08-08 |
Family
ID=55629490
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA040781A MA40781A (fr) | 2014-10-01 | 2015-05-28 | Composition pharmaceutique d'isotrétinoïne à faible dosage destinée à la voie orale |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20160128962A1 (fr) |
| EP (1) | EP3200877A4 (fr) |
| JP (1) | JP6707532B2 (fr) |
| AU (1) | AU2015326489A1 (fr) |
| BR (1) | BR112017006779A2 (fr) |
| CA (2) | CA3207801A1 (fr) |
| MA (1) | MA40781A (fr) |
| MX (2) | MX377579B (fr) |
| RU (1) | RU2707753C2 (fr) |
| WO (1) | WO2016051288A1 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015294993A1 (en) * | 2014-07-31 | 2017-02-16 | Sun Pharmaceutical Industries Limited | Oral pharmaceutical composition of isotretinoin |
| US10517846B2 (en) | 2016-05-26 | 2019-12-31 | Dr. Reddy's Laboratories Ltd. | Pharmaceutical compositions for treating acne |
| WO2018073751A1 (fr) * | 2016-10-17 | 2018-04-26 | Sun Pharmaceutical Industries Limited | Procédé de traitement de l'acné |
| US10716774B1 (en) | 2018-01-05 | 2020-07-21 | Yale Pharmaceuticals LLC | Pharmaceutical compositions containing isotretinoin with improved dissolution profile and enhanced stability |
| JP2024178478A (ja) * | 2021-11-04 | 2024-12-25 | 興和株式会社 | 医薬品 |
| JP2024178477A (ja) * | 2021-11-04 | 2024-12-25 | 興和株式会社 | カプセル剤 |
| KR20250054055A (ko) | 2022-07-01 | 2025-04-22 | 아크로테크 바이오파마 인코포레이티드. | 이소트레티노인을 포함하는 제약 조성물 및 그의 제조 방법 및 용도 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20001227A1 (es) * | 1998-10-30 | 2000-11-06 | Hoffmann La Roche | Procesos para producir una composicion de isotretinoina |
| US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
| FR2807662A1 (fr) * | 2000-04-12 | 2001-10-19 | Cll Pharma | Procede pour stabiliser la granulometrie d'un principe actif verulent disperse dans un liquide et ses applications |
| AU2001289438A1 (en) * | 2000-09-22 | 2002-04-02 | Galephar M/F | Pharmaceutical semi-solid composition of isotretinoin |
| BR0117191A (pt) * | 2001-12-06 | 2005-05-10 | Ranbaxy Lab Ltd | Composições nanoparticuladas de isotretinoina |
| WO2012053013A2 (fr) * | 2010-10-21 | 2012-04-26 | Cadila Healthcare Limited | Compositions pharmaceutiques d'agents anti-acné |
| EP2667842A1 (fr) * | 2011-01-24 | 2013-12-04 | Anterios, Inc. | Compositions de tensio-actifs |
| US9078925B2 (en) * | 2012-06-18 | 2015-07-14 | Galephar Pharmaceutical Research, Inc. | Pharmaceutical semi-solid composition of isotretinoin |
| BR112017025427A2 (pt) * | 2015-05-25 | 2018-08-07 | Sun Pharmaceutical Ind Ltd | composição farmacêutica oral |
-
2015
- 2015-05-28 MA MA040781A patent/MA40781A/fr unknown
- 2015-05-29 MX MX2017004312A patent/MX377579B/es active IP Right Grant
- 2015-05-29 BR BR112017006779-0A patent/BR112017006779A2/pt not_active Application Discontinuation
- 2015-05-29 CA CA3207801A patent/CA3207801A1/fr active Pending
- 2015-05-29 JP JP2017517643A patent/JP6707532B2/ja active Active
- 2015-05-29 WO PCT/IB2015/054080 patent/WO2016051288A1/fr not_active Ceased
- 2015-05-29 RU RU2017114924A patent/RU2707753C2/ru active
- 2015-05-29 AU AU2015326489A patent/AU2015326489A1/en not_active Abandoned
- 2015-05-29 CA CA2963206A patent/CA2963206C/fr active Active
- 2015-05-29 EP EP15845766.3A patent/EP3200877A4/fr not_active Withdrawn
- 2015-12-03 US US14/958,467 patent/US20160128962A1/en not_active Abandoned
-
2017
- 2017-03-31 MX MX2020009444A patent/MX2020009444A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP6707532B2 (ja) | 2020-06-10 |
| JP2017530149A (ja) | 2017-10-12 |
| US20160128962A1 (en) | 2016-05-12 |
| CA2963206C (fr) | 2023-09-26 |
| RU2017114924A3 (fr) | 2019-01-16 |
| MX377579B (es) | 2025-03-10 |
| AU2015326489A1 (en) | 2017-04-27 |
| WO2016051288A1 (fr) | 2016-04-07 |
| BR112017006779A2 (pt) | 2018-01-09 |
| MX2017004312A (es) | 2017-07-07 |
| RU2017114924A (ru) | 2018-11-02 |
| CA2963206A1 (fr) | 2016-04-07 |
| EP3200877A4 (fr) | 2018-05-23 |
| EP3200877A1 (fr) | 2017-08-09 |
| RU2707753C2 (ru) | 2019-11-29 |
| CA3207801A1 (fr) | 2016-04-07 |
| MX2020009444A (es) | 2020-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3256138A4 (fr) | Compositions pharmaceutiques contenant du méloxicam | |
| EP3565550A4 (fr) | Compositions pharmaceutiques contenant du méloxicam | |
| PL3717471T3 (pl) | Nowe związki i zawierające je kompozycje farmaceutyczne do leczenia chorób | |
| EP3621621A4 (fr) | Compositions pharmaceutiques contenant du méloxicam | |
| EP3493799A4 (fr) | Composition pharmaceutique decannabis | |
| EP3294212A4 (fr) | Administration de médicament à partir d'hydrogels | |
| MA52257A (fr) | Compositions pharmaceutiques comprenant blautia et leur administration orale | |
| EP3256149A4 (fr) | Formulations pour administration orale d'agents actifs | |
| MA40781A (fr) | Composition pharmaceutique d'isotrétinoïne à faible dosage destinée à la voie orale | |
| MA54716A (fr) | Réduction de la viscosité de formulations pharmaceutiques | |
| DK3116491T3 (da) | Farmaceutiske sammensætninger af terapeutisk aktive forbindelser | |
| MA46867A (fr) | Formulations pharmaceutiques | |
| HUE062579T2 (hu) | Baktériumokat tartalmazó orális gyógyszerészeti formuláció | |
| MA42303A (fr) | Formulations pharmaceutiques | |
| MA43705A (fr) | Formulation pharmaceutique | |
| EP3310439A4 (fr) | Compositions pharmaceutiques pour des applications anesthésiologiques | |
| FR3022462B1 (fr) | Composition orale d'anticorps anti-tnfalpha | |
| FR3027521B1 (fr) | Compositions pour administration par voie orale | |
| MA47516A (fr) | Composition pharmaceutique | |
| BR112017013012A2 (pt) | compostos de indenil, composições farmacêuticas e usos médicos destes | |
| IL269884B1 (en) | Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor | |
| EP3318259A4 (fr) | Composition pharmaceutique stable pour administration par voie orale | |
| EP2964195A4 (fr) | Composition semi-solide pharmaceutique d'isotrétinoïne | |
| MA49837A (fr) | Compositions pharmaceutiques | |
| MA45158A (fr) | Composition pharmaceutique comprenant de l'éteplirsen |